A new study from Bioethics International shows that a majority of drugs provided to very ill patients via the Food and Drug Administration’s (FDA) expanded access program – 76% – eventually gain marketing approval from FDA. However, few safety and efficacy data from expanded access uses are reported to the public before such approval. http://prn.to/2vtgDeN
- What information can the donation of one patient’s tumor yield about metastasis?
- What is the iMPACT Program and how will it bring diversity to clinical trials?
- How is it possible that a great many promising cancer drugs create a problem for research and trials?
- Research Ethics Education a critical priority for WCGF: New Grant Opportunities Offered.
- How are physicians and researchers working to make clinical trials more diverse?